Immunological Effects of Silica and Related Dysregulation of Autoimmunity

Naoko Kumagai1, Hiroaki Hayashi2, Megumi Maeda1, Yoshie Miura3, Hidenori Matsuzaki1, Suni Lee1, Yasumitsu Nishimura1, Wataru Fujimoto2 and Takemi Otsuki1 1Department of Hygiene, 2Department of Dermatology, 1,2Kawasaki Medical School, Kurashiki, 3Division of Molecular and Clinical Genetics, Department of Molecular Genetics, Medical Institute of Bioregulation, Kyushu University, Higashi-ku, Fukuoka, Japan

[1]  Clio P. Mavragani,et al.  Autoimmune Disorders - Pathogenetic Aspects , 2011 .

[2]  T. Otsuki,et al.  Dysregulation of the immune system caused by silica and asbestos , 2010, Journal of immunotoxicology.

[3]  S. Murakami,et al.  Reductive Alteration of the Regulatory Function of the CD4+CD25+ T Cell Fraction in Silicosis Patients , 2010, International journal of immunopathology and pharmacology.

[4]  H. Hoffman,et al.  Inflammasome and IL-1β-Mediated Disorders , 2010, Current allergy and asthma reports.

[5]  M. Amagai,et al.  Immune dysregulation of pemphigus in humans and mice , 2010, The Journal of dermatology.

[6]  S. Toyokuni.  Mechanisms of asbestos-induced carcinogenesis. , 2011, Nagoya journal of medical science.

[7]  G. Cooper,et al.  Recent advances and opportunities in research on lupus: environmental influences and mechanisms of disease. , 2009, Ciencia & saude coletiva.

[8]  Daohai Yu,et al.  PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+ CD25(Hi) regulatory T cells. , 2009, International immunology.

[9]  Amit Awasthi,et al.  Th17 cells: from precursors to players in inflammation and infection. , 2009, International immunology.

[10]  R. de Waal Malefyt,et al.  Development and function of TH17 cells in health and disease. , 2009, The Journal of allergy and clinical immunology.

[11]  A. Holian,et al.  Critical role of MARCO in crystalline silica-induced pulmonary inflammation. , 2009, Toxicological sciences : an official journal of the Society of Toxicology.

[12]  T. Otsuki,et al.  Cytokine alteration and speculated immunological pathophysiology in silicosis and asbestos-related diseases , 2009, Environmental health and preventive medicine.

[13]  T. Brown.  Silica exposure, smoking, silicosis and lung cancer--complex interactions. , 2009, Occupational medicine.

[14]  S. Murakami,et al.  Soluble Interleukin-2 Receptor as an Indicator of Immunological Disturbance Found in Silicosis Patients , 2009, International journal of immunopathology and pharmacology.

[15]  Yigong Shi,et al.  FLIP and the death effector domain family , 2008, Oncogene.

[16]  M. Clerici,et al.  CD4+CD25+FoxP3+PD1— regulatory T cells in acute and stable relapsing‐remitting multiple sclerosis and their modulation by therapy , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[17]  K. Rock,et al.  Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization , 2008, Nature Immunology.

[18]  Richard A. Flavell,et al.  The Nalp3 inflammasome is essential for the development of silicosis , 2008, Proceedings of the National Academy of Sciences.

[19]  Dennis J Paustenbach,et al.  State-of-the-Science Review of the Occupational Health Hazards of Crystalline Silica in Abrasive Blasting Operations and Related Requirements for Respiratory Protection , 2008, Journal of toxicology and environmental health. Part B, Critical reviews.

[20]  L. Greillier,et al.  Mesothelioma and Asbestos-Related Pleural Diseases , 2008, Respiration.

[21]  J. Tschopp,et al.  Innate Immune Activation Through Nalp3 Inflammasome Sensing of Asbestos and Silica , 2008, Science.

[22]  R. Hamilton,et al.  Silica binding and toxicity in alveolar macrophages. , 2008, Free radical biology & medicine.

[23]  T. Nakano,et al.  Immunological alterations found in mesothelioma patients and supporting experimental evidence , 2008, Environmental health and preventive medicine.

[24]  S. Anderton,et al.  Foxp3+ regulatory T cells in the control of experimental CNS autoimmune disease , 2008, Journal of Neuroimmunology.

[25]  Yong Zhao,et al.  The inflammatory Th 17 subset in immunity against self and non-self antigens , 2008, Autoimmunity.

[26]  M. Veldhoen,et al.  Th17 T cells: linking innate and adaptive immunity. , 2007, Seminars in immunology.

[27]  T. Nakano,et al.  Immunological effects of silica and asbestos. , 2007, Cellular & molecular immunology.

[28]  D Rees,et al.  Silica, silicosis and tuberculosis. , 2007, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[29]  P. Miossec,et al.  The role of T cells in rheumatoid arthritis: new subsets and new targets , 2007, Current opinion in rheumatology.

[30]  Graham M Lord,et al.  The role of T helper 17 (Th17) and regulatory T cells (Treg) in human organ transplantation and autoimmune disease , 2007, Clinical and experimental immunology.

[31]  S. Rutella,et al.  The Janus face of CD4+CD25+ regulatory T cells in cancer and autoimmunity. , 2007, Current medicinal chemistry.

[32]  J. McCune,et al.  Human CD4+ regulatory T cells express lower levels of the IL-7 receptor alpha chain (CD127), allowing consistent identification and sorting of live cells. , 2007, Journal of immunological methods.

[33]  H. Nishimura,et al.  Silica-associated systemic lupus erythematosus in an elderly man. , 2007, Internal medicine.

[34]  M. Dosemeci,et al.  Lung cancer among silica-exposed workers: the quest for truth between chance and necessity. , 2007, La Medicina del lavoro.

[35]  A. Holian,et al.  Silica-directed mast cell activation is enhanced by scavenger receptors. , 2007, American journal of respiratory cell and molecular biology.

[36]  R. Geffers,et al.  Naive regulatory T cells: a novel subpopulation defined by resistance toward CD95L-mediated cell death. , 2006, Blood.

[37]  R. Hamilton,et al.  MARCO Mediates Silica Uptake and Toxicity in Alveolar Macrophages from C57BL/6 Mice* , 2006, Journal of Biological Chemistry.

[38]  P. Mudd,et al.  Regulatory T Cells and Systemic Lupus Erythematosus , 2006, Scandinavian journal of immunology.

[39]  K. Kretschmer,et al.  Making regulatory T cells with defined antigen specificity: role in autoimmunity and cancer , 2006, Immunological reviews.

[40]  T. Gingeras,et al.  CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells , 2006, The Journal of experimental medicine.

[41]  A. Šedivá,et al.  Exposure to silica and risk of ANCA-associated vasculitis. , 2006, American journal of industrial medicine.

[42]  C. la Vecchia,et al.  Occupational silica exposure and lung cancer risk: a review of epidemiological studies 1996-2005. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[43]  L. Harrington,et al.  Expanding the effector CD4 T-cell repertoire: the Th17 lineage. , 2006, Current opinion in immunology.

[44]  A. Ueki,et al.  Alterations of Fas and Fas-Related Molecules in Patients with Silicosis , 2006, Experimental biology and medicine.

[45]  H. Sakaguchi,et al.  Reduced Function of CD4+25+ Regulatory T Cell Fraction in Silicosis Patients , 2006, International journal of immunopathology and pharmacology.

[46]  J. Bluestone,et al.  How do CD4+CD25+ regulatory T cells control autoimmunity? , 2005, Current opinion in immunology.

[47]  W. Fujimoto,et al.  Detection, epitope‐mapping and function of anti‐Fas autoantibody in patients with silicosis , 2005, Immunology.

[48]  P. Krammer,et al.  Cutting Edge: In Contrast to Effector T Cells, CD4+CD25+FoxP3+ Regulatory T Cells Are Highly Susceptible to CD95 Ligand- but Not to TCR-Mediated Cell Death1 , 2005, The Journal of Immunology.

[49]  S. Chattopadhyay,et al.  Regulatory T cells and tumor immunity , 2005, Cancer Immunology, Immunotherapy.

[50]  Ping Wu,et al.  Induction of CD69 antigen expression in peripheral blood mononuclear cells on exposure to silica, but not by asbestos/chrysotile-A. , 2005, Immunology letters.

[51]  R. Schwartz,et al.  Natural regulatory T cells and self-tolerance , 2005, Nature Immunology.

[52]  W. Rom,et al.  Basic pathogenetic mechanisms in silicosis: current understanding , 2005, Current opinion in pulmonary medicine.

[53]  Y. Takasaki,et al.  Soluble Fas molecule in the serum of patients with systemic lupus erythematosus , 1996, Journal of Clinical Immunology.

[54]  P. Krammer,et al.  In contrast to effector T cells, CD4+CD25+FoxP3+ regulatory T cells are highly susceptible to CD95 ligand- but not to TCR-mediated cell death. , 2005, Journal of immunology.

[55]  C. Baecher-Allan,et al.  Human CD4+CD25+ regulatory T cells. , 2004, Seminars in immunology.

[56]  K. Mulloy.  Silica exposure and systemic vasculitis. , 2003, Environmental health perspectives.

[57]  T. Cotter,et al.  Live and let die: regulatory mechanisms in Fas-mediated apoptosis. , 2003, Cellular signalling.

[58]  Robert Cohen,et al.  Update on respiratory disease from coal mine and silica dust. , 2002, Clinics in chest medicine.

[59]  Y. Isozaki,et al.  Intramolecular epitope spreading among anti‐caspase‐8 autoantibodies in patients with silicosis, systemic sclerosis and systemic lupus erythematosus, as well as in healthy individuals , 2002, Clinical and experimental immunology.

[60]  S. Yonehara.  Death receptor Fas and autoimmune disease: from the original generation to therapeutic application of agonistic anti-Fas monoclonal antibody. , 2002, Cytokine & growth factor reviews.

[61]  D. Landsittel,et al.  Enhanced nitric oxide and reactive oxygen species production and damage after inhalation of silica. , 2002, American journal of physiology. Lung cellular and molecular physiology.

[62]  H. Sakaguchi,et al.  Autoantibodies detectable in the sera of silicosis patients. The relationship between the anti-topoisomerase I antibody response and HLA-DQB1*0402 allele in Japanese silicosis patients. , 2001, The Science of the total environment.

[63]  A. Ueki,et al.  Antidesmoglein Autoantibodies in Silicosis Patients with No Bullous Diseases , 2001, Dermatology.

[64]  H. Sakaguchi,et al.  Is the anti-topoisomerase I autoantibody response associated with a distinct amino acid sequence in the HLA-DQbeta1 domain? , 2001, Arthritis and rheumatism.

[65]  Toshiyuki Shimizu,et al.  Reduced Expression of the Survivin Gene in PBMC from Silicosis Patients , 2001 .

[66]  D. Hemenway,et al.  Lymphocytes, lymphokines, and silicosis. , 2001, Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer.

[67]  C. Giardina,et al.  Cellular and molecular mechanisms regulating silica-induced adhesion molecule expression in mice. , 2001, Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer.

[68]  H. Sakaguchi,et al.  Reduced Expression of the Inhibitory Genes for Fas‐Mediated Apoptosis in Silicosis Patients , 2000 .

[69]  H. Sakaguchi,et al.  Detection of alternatively spliced variant messages of Fas gene and mutational screening of Fas and Fas ligand coding regions in peripheral blood mononuclear cells derived from silicosis patients. , 2000, Immunology letters.

[70]  Otsuki,et al.  Over‐expression of the decoy receptor 3 (DcR3) gene in peripheral blood mononuclear cells (PBMC) derived from silicosis patients , 2000, Clinical and experimental immunology.

[71]  坂平 英樹.  Cleavage of CAD inhibitor in CAD activation and DNA degradation during apoptosis , 2000 .

[72]  Kishimoto,et al.  Serum levels of soluble Fas ligand in patients with silicosis , 1999, Clinical and experimental immunology.

[73]  H. Sakaguchi,et al.  Evaluation of cases with silicosis using the parameters related to Fas-mediated apoptosis. , 1999, International journal of molecular medicine.

[74]  G. Cooper,et al.  Occupational exposure to crystalline silica and autoimmune disease. , 1999, Environmental health perspectives.

[75]  J. Finkelstein,et al.  Silica-induced chemokine expression in alveolar type II cells is mediated by TNF-alpha-induced oxidant stress. , 1999, The American journal of physiology.

[76]  J. Finkelstein,et al.  Silica-induced chemokine expression in alveolar type II cells is mediated by TNF-α-induced oxidant stress. , 1999, American journal of physiology. Lung cellular and molecular physiology.

[77]  S. Sabol,et al.  Inhibition of apoptosis-associated DNA fragmentation activity in nonapoptotic cells: the role of DNA fragmentation factor-45 (DFF45/ICAD). , 1998, Biochemical and biophysical research communications.

[78]  U. Anderegg,et al.  Silica induced scleroderma--clinical and experimental aspects. , 1998, The Journal of rheumatology.

[79]  S. Nagata.  Human autoimmune lymphoproliferative syndrome, a defect in the apoptosis-inducing Fas receptor: A lesson from the mouse model , 1998, Journal of Human Genetics.

[80]  D. Shanklin,et al.  The immunopathology of siliconosis , 1998, Immunologic research.

[81]  B. Nelson,et al.  Biology of the interleukin-2 receptor. , 1998, Advances in immunology.

[82]  C. Kallenberg,et al.  Silicon exposure and vasculitis. , 1998, Current opinion in rheumatology.

[83]  Y. Isozaki,et al.  Elevated soluble Fas/APO‐1 (CD95) levels in silicosis patients without clinical symptoms of autoimmune diseases or malignant tumours , 1997, Clinical and experimental immunology.

[84]  P. Krammer,et al.  The CD95 system and the death of a lymphocyte. , 1997, Seminars in immunology.

[85]  S. Nagata,et al.  Fas-mediated apoptosis. , 1996, Advances in experimental medicine and biology.

[86]  C. Rudin,et al.  Apoptotic signaling in lymphocytes , 1996, Current opinion in hematology.

[87]  P. Krammer,et al.  Levels of soluble Fas/APO-1/CD95 in systemic lupus erythematosus and juvenile rheumatoid arthritis. , 1995, Arthritis and rheumatism.

[88]  K. Steenland,et al.  Silica exposure and autoimmune diseases. , 1995, American journal of industrial medicine.

[89]  S. Nagata,et al.  The Fas death factor , 1995, Science.

[90]  S. Nagata,et al.  Fas and Fas ligand: lpr and gld mutations. , 1995, Immunology today.

[91]  A. Kuryliszyn-Moskal,et al.  Apoptosis in autoimmune diseases. , 1995, Roczniki Akademii Medycznej w Bialymstoku.

[92]  Matthew J. Brauer,et al.  Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. , 1994, Science.

[93]  A. Steinberg.  MRL-lpr/lpr disease: theories meet Fas. , 1994, Seminars in immunology.

[94]  J. Mountz,et al.  Murine models of autoimmunity: T‐cell and B‐cell defects , 1992, Current opinion in rheumatology.

[95]  Carlson Ih.  New markers in serum for lymphocyte activation for predicting allograft rejection. Neopterin and soluble interleukin-2 receptor. , 1992 .

[96]  I. Carlson.  New markers in serum for lymphocyte activation for predicting allograft rejection. Neopterin and soluble interleukin-2 receptor. , 1992, Clinics in Laboratory Medicine.

[97]  B. Zerler.  The soluble interleukin-2 receptor as a marker for human neoplasia and immune status. , 1991, Cancer cells.

[98]  G. Pizzolo.  The soluble interleukin-2 receptor as a new biological marker in diseases. , 1991, Allergologia et immunopathologia.

[99]  L A Rubin,et al.  The soluble interleukin-2 receptor: biology, function, and clinical application. , 1990, Annals of internal medicine.

[100]  U. Haustein,et al.  Silica-induced scleroderma. , 1990, Journal of the American Academy of Dermatology.

[101]  P. Grambsch,et al.  Soluble interleukin-2 receptor level as an indicator of liver allograft rejection. , 1989, Transplantation.

[102]  R. Cowie.  Silica-dust-exposed mine workers with scleroderma (systemic sclerosis). , 1987, Chest.

[103]  A. Tuneu,et al.  Impotence in silicosis-associated scleroderma. , 1986, Journal of American Academy of Dermatology.

[104]  P. Hessel,et al.  Silica, silicosis, and progressive systemic sclerosis. , 1985, British journal of industrial medicine.

[105]  R. A. McReynolds,et al.  Immunotoxicology of silica. , 1982, Critical reviews in toxicology.

[106]  P. Mahieu,et al.  Asbestosis and systemic lupus erythematosus. , 1980, International archives of allergy and applied immunology.

[107]  R. B. Payne,et al.  A Broader Concept of Caplan's Syndrome Related to Rheumatoid Factors , 1962, Thorax.

[108]  A. Caplan.  Rheumatoid Disease and Pneumoconiosis (Caplan's Syndrome) , 1959, Proceedings of the Royal Society of Medicine.